TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis.
Hepatobiliary Surg Nutr
; 2(5): 260-5, 2013 Oct.
Article
em En
| MEDLINE
| ID: mdl-24570956
ABSTRACT
BACKGROUND:
Various studies examined the relationship between p53 mutation with the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results.METHODS:
Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between p53 mutation and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed.RESULTS:
We performed a meta-analysis of 9 studies that evaluated the correlation between p53 mutation and survival in patients with HCC. Combined hazard ratios suggested that p53 mutation had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.46, 95% confidence interval (CI) 1.15-1.76], and disease free survival (DFS) (HR =2.57, 95% CI 1.46-3.68) in patients with HCC. The significant heterogeneity (P=0.035) was observed among 8 studies for OS, however no significant heterogeneity (P=0.597) was observed among 5 studies for DFS.CONCLUSIONS:
p53 mutation indicates a poor prognosis for patients with hepatocellular carcinoma.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Risk_factors_studies
/
Systematic_reviews
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article